Roseline Godbout
Contact
Faculty of Medicine & Dentistry - Oncology Dept
- rgodbout@ualberta.ca
- Phone
- (780) 432-8901
- Address
-
Cross Cancer Institute
11560 University AvenueEdmonton ABT6G 1Z2
Overview
Area of Study / Keywords
About
Dr. Roseline Godbout is currently appointed as Professor in the Department of Oncology in the Faculty of Medicine & Dentistry.Research
My research group has three main areas of interest: (i) regulation of gene expression during retinal development (see Project Details – Project 1), (ii) characterization of a DEAD box protein called DDX1 in the human tumour of the retina called retinoblastoma (Project 2), and (iii) induction of differentiation in brain tumours (Project 3)Projects 1 and 2: Retinoblastoma, a childhood tumour of the eye, occurs when both copies of the retinoblastoma (RB) gene are mutated in retinal precursor cells. In spite of extensive investigations of the RB gene, no one truly understands how retinal precursor cells become tumorigenic. We are using different approaches spanning the fields of molecular biology, cellular biology and developmental biology, to study the spectrum of changes in retinal cells compared to retinoblastoma tumour cells.
Project 3: Malignant gliomas are deadly brain tumours that are extremely aggressive and hard to treat. We believe that malignant glioma tumours are derived from a glial cell that is normally highly invasive during brain development. We propose that a better understanding of the genes expressed in normal glial cells will shed light on how to control the aggressive properties of brain tumours.?
Courses
ONCOL 425 - Advanced Topics in Cancer Research
This course provides an in-depth analysis of selected topics in cancer research. The course features three modules, each covering a different area of cancer research. Modules 1 - 3 and Modules 4 - 6 will be offered in alternate years. Each module is comprised of 8 sessions of 80 min each, with each module taught as an independent unit. Modules have both lecture and group discussion components. Students can take both offerings (modules 1 through 3 and modules 4 through 6) up to a maximum of six credits. Prerequisite: CELL 201/BIOL 201 and a 300 level science course in BIOCH, GENET, ONCOL, CELL or consent of the Department.
ONCOL 525 - Advanced Topics in Cancer
This course provides an in-depth analysis of selected topics in cancer research. The course features three modules, each covering a different area of cancer research. Modules 1 - 3 and Modules 4 - 6 will be offered in alternate years. Each module is comprised of 8 sessions of 80 min each, with each module taught as an independent unit. Modules have both lecture and group discussion components. Lectures are the same as for ONCOL 425, but with additional assignments and evaluation appropriate to graduate studies. This course may not be taken for credit if credit has already been obtained in ONCOL 425. Prerequisite: CELL 201/BIOL 201 and a 300 level science course in BIOCH, GENET, ONCOL, CELL or consent of the Department.
ONCOL 620 - Recent Advances in Cancer Research
A directed reading and seminar course based on recent developments in the cellular and molecular biology of cancer. The students will critically review papers selected from the recent literature and give oral presentations. Prerequisites: ONCOL 520 and consent of Department. Offered in alternate years.
Featured Publications
Combining an Oncolytic Vaccinia Virus with ImageGuided Radiotherapy for Improving Treatment of Glioblastoma.
Canadian Society for Virology 4th Symposium, Edmonton . 2022 June;
Role of DDX1 and ATM in Ataxia Telangiectasia Cellular Response to Stress.
Women and Children’s Health Research Institute Research Day, Edmonton. 2021 November;
MYC mediates retinoic acid resistance by inhibiting CRABP2-RARa pathway in HER2-enriched breast cancers.
Canadian Cancer Research Conference. 2021 November;
Role of NFIB in metastasis of p53-mutated triple-negative breast cancer.
Canadian Cancer Research Conference . 2021 November;
Role of Brain Fatty Acid Binding Protein in Glioblastoma Microtube Formation
2021 Alberta Cancer Research Conference . 2021 October;
Choi W.S., Xu X., Goruk S., Wang Y., Patel S., Chow M., Field C.J., Godbout R.
Nutrients. 2021 August; 13 (8):1-16 10.3390/nu13082664
DNA damage repair and DEAD Box 1 (DDX1) in embryonic development.
Helicases and Nucleic Acid-Based Machines: Structure, Mechanism and Regulation and Roles in Human Disease Conference (International virtual conference). 2021 July;
Cancer Research 81 (13 Supplement) . 2021 July; 10.1158/1538-7445. AM2021-1401
DEAD box 1 (DDX1) stabilizes cytoplasmic mRNAs during oxidative stress.
Helicases and Nucleic Acid-Based Machines: Structure, Mechanism and Regulation and Roles in Human Disease Conference (International virtual conference). 2021 July;
Cancer Research 81 (13 Supplement) . 2021 July; 10.1158/1538-7445.AM2021-2886.
Xu X., Wang Y., Choi W.S., Sun X., Godbout R.
Nanoscale. 2021 June; 13 (21):9706-9722 10.1039/d1nr02128a
Brain fatty acid-binding protein and polyunsaturated fatty acids: Investigating their effect on glioblastoma membrane phospholipid composition and membrane fluidity.
American Association for Cancer Research (AACR) Annual Meeting. 2021 April;
MYC mediates retinoic acid resistance by suppressing CRABP2 transcription in HER2-enriched breast cancers
American Association for Cancer Research (AACR) Annual Meeting. 2021 April;
Liu R.Z., Godbout R.
Cancers. 2020 December; 12 (12):1-19 10.3390/cancers12123823
Neuro-Oncology Vol 22, December 2020, Page iii295. 2020 December; doi-org.10.1093/neuonc/noaa222.090
Bharadwaj A.G., Dahn M.L., Liu R.Z., Colp P., Thomas L.N., Holloway R.W., Marignani P.A., Too C.K.L., Barnes P.J., Godbout R., Marcato P., Waisman D.M.
Cancers. 2020 December; 12 (12):1-22 10.3390/cancers12123673
Liu R.Z., Choi W.S., Jain S., Dinakaran D., Xu X., Han W.H., Yang X.H., Glubrecht D.D., Moore R.B., Lemieux H., Godbout R.
Molecular Oncology. 2020 December; 14 (12):3100-3120 10.1002/1878-0261.12818